$JUNO Insider Trading
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in Juno Therapeutics, Inc..
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of all insider trading transactions in Juno Therapeutics, Inc.. Get notifications about new insider transactions in Juno Therapeutics, Inc. for free.
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 07 2018 | JUNO | Juno Therapeutics, ... | Wilderotter Mary Agnes | Director | Option Exercise | D | 23.29 | 12,000 | 279,480 | 0 | |
| Mar 07 2018 | JUNO | Juno Therapeutics, ... | Wilderotter Mary Agnes | Director | Option Exercise | D | 42.40 | 12,000 | 508,800 | 0 | |
| Mar 07 2018 | JUNO | Juno Therapeutics, ... | Wilderotter Mary Agnes | Director | Option Exercise | D | 60.00 | 12,000 | 720,000 | 0 | |
| Mar 07 2018 | JUNO | Juno Therapeutics, ... | Wilderotter Mary Agnes | Director | Option Exercise | D | 8.72 | 75,000 | 654,000 | 0 | |
| Mar 07 2018 | JUNO | Juno Therapeutics, ... | PIEN HOWARD H | Director | Option Exercise | D | 23.29 | 12,000 | 279,480 | 0 | |
| Mar 07 2018 | JUNO | Juno Therapeutics, ... | PIEN HOWARD H | Director | Option Exercise | D | 42.40 | 12,000 | 508,800 | 0 | |
| Mar 07 2018 | JUNO | Juno Therapeutics, ... | PIEN HOWARD H | Director | Option Exercise | D | 60.00 | 12,000 | 720,000 | 0 | |
| Mar 07 2018 | JUNO | Juno Therapeutics, ... | PIEN HOWARD H | Director | Sell | D | 87.00 | 5,050 | 439,350 | 0 | 5.1 K to 0 (-100.00 %) |
| Mar 07 2018 | JUNO | Juno Therapeutics, ... | PIEN HOWARD H | Director | Sell | U | 87.00 | 111,587 | 9,708,069 | 5,050 | 116.6 K to 5.1 K (-95.67 %) |
| Mar 07 2018 | JUNO | Juno Therapeutics, ... | PIEN HOWARD H | Director | Gift | G | 0.00 | 1,162 | 0 | 116,637 | 117.8 K to 116.6 K (-0.99 %) |
| Mar 07 2018 | JUNO | Juno Therapeutics, ... | PIEN HOWARD H | Director | Gift | G | 0.00 | 12,251 | 0 | 117,799 | 130.1 K to 117.8 K (-9.42 %) |
| Mar 07 2018 | JUNO | Juno Therapeutics, ... | NELSEN ROBERT | Director | Option Exercise | D | 23.29 | 12,000 | 279,480 | 0 | |
| Mar 07 2018 | JUNO | Juno Therapeutics, ... | NELSEN ROBERT | Director | Option Exercise | D | 42.40 | 12,000 | 508,800 | 0 | |
| Mar 07 2018 | JUNO | Juno Therapeutics, ... | NELSEN ROBERT | Director | Option Exercise | D | 60.00 | 12,000 | 720,000 | 0 | |
| Mar 07 2018 | JUNO | Juno Therapeutics, ... | NELSEN ROBERT | Director | Sell | U | 87.00 | 10,552,390 | 918,057,930 | 0 | 10.6 M to 0 (-100.00 %) |
| Mar 07 2018 | JUNO | Juno Therapeutics, ... | NELSEN ROBERT | Director | Sell | D | 87.00 | 3,234 | 281,358 | 0 | 3.2 K to 0 (-100.00 %) |
| Mar 07 2018 | JUNO | Juno Therapeutics, ... | NELSEN ROBERT | Director | Sell | U | 87.00 | 50,824 | 4,421,688 | 3,234 | 54.1 K to 3.2 K (-94.02 %) |
| Mar 07 2018 | JUNO | Juno Therapeutics, ... | LEE ANN L. | EVP, Technical Oper ... | Option Exercise | D | 62.85 | 152,900 | 9,609,765 | 0 | |
| Mar 07 2018 | JUNO | Juno Therapeutics, ... | LEE ANN L. | EVP, Technical Oper ... | Sell | D | 0.00 | 35,000 | 0 | 0 | 35 K to 0 (-100.00 %) |
| Mar 07 2018 | JUNO | Juno Therapeutics, ... | LEE ANN L. | EVP, Technical Oper ... | Sell | D | 0.00 | 40,788 | 0 | 35,000 | 75.8 K to 35 K (-53.82 %) |
| Mar 07 2018 | JUNO | Juno Therapeutics, ... | LEE ANN L. | EVP, Technical Oper ... | Sell | D | 0.00 | 35,004 | 0 | 75,788 | 110.8 K to 75.8 K (-31.59 %) |
| Mar 07 2018 | JUNO | Juno Therapeutics, ... | Klausner Richard | Director | Option Exercise | D | 23.29 | 12,000 | 279,480 | 0 | |
| Mar 07 2018 | JUNO | Juno Therapeutics, ... | Klausner Richard | Director | Option Exercise | D | 42.40 | 12,000 | 508,800 | 0 | |
| Mar 07 2018 | JUNO | Juno Therapeutics, ... | Klausner Richard | Director | Option Exercise | D | 60.00 | 12,000 | 720,000 | 0 | |
| Mar 07 2018 | JUNO | Juno Therapeutics, ... | Klausner Richard | Director | Sell | U | 87.00 | 705,525 | 61,380,675 | 0 | 705.5 K to 0 (-100.00 %) |
| Mar 07 2018 | JUNO | Juno Therapeutics, ... | Klausner Richard | Director | Gift | G | 0.00 | 23,250 | 0 | 705,525 | 728.8 K to 705.5 K (-3.19 %) |
| Mar 07 2018 | JUNO | Juno Therapeutics, ... | Harr Steve | CFO & Head, Corp. D ... | Option Exercise | D | 20.76 | 127,841 | 2,653,979 | 0 | |
| Mar 07 2018 | JUNO | Juno Therapeutics, ... | Harr Steve | CFO & Head, Corp. D ... | Option Exercise | D | 24.50 | 155,000 | 3,797,500 | 0 | |
| Mar 07 2018 | JUNO | Juno Therapeutics, ... | Harr Steve | CFO & Head, Corp. D ... | Option Exercise | D | 48.06 | 85,000 | 4,085,100 | 0 | |
| Mar 07 2018 | JUNO | Juno Therapeutics, ... | Harr Steve | CFO & Head, Corp. D ... | Option Exercise | D | 8.72 | 98,750 | 861,100 | 0 | |
| Mar 07 2018 | JUNO | Juno Therapeutics, ... | Harr Steve | CFO & Head, Corp. D ... | Sell | D | 0.00 | 35,893 | 0 | 0 | 35.9 K to 0 (-100.00 %) |
| Mar 07 2018 | JUNO | Juno Therapeutics, ... | Harr Steve | CFO & Head, Corp. D ... | Sell | D | 0.00 | 11,544 | 0 | 35,893 | 47.4 K to 35.9 K (-24.34 %) |
| Mar 07 2018 | JUNO | Juno Therapeutics, ... | Harr Steve | CFO & Head, Corp. D ... | Sell | D | 0.00 | 29,135 | 0 | 47,437 | 76.6 K to 47.4 K (-38.05 %) |
| Mar 07 2018 | JUNO | Juno Therapeutics, ... | Harr Steve | CFO & Head, Corp. D ... | Sell | D | 0.00 | 20,580 | 0 | 76,572 | 97.2 K to 76.6 K (-21.18 %) |
| Mar 07 2018 | JUNO | Juno Therapeutics, ... | Harr Steve | CFO & Head, Corp. D ... | Sell | D | 87.00 | 50,010 | 4,350,870 | 97,152 | 147.2 K to 97.2 K (-33.98 %) |
| Mar 07 2018 | JUNO | Juno Therapeutics, ... | Harr Steve | CFO & Head, Corp. D ... | Sell | U | 87.00 | 492,355 | 42,834,885 | 147,162 | 639.5 K to 147.2 K (-76.99 %) |
| Mar 07 2018 | JUNO | Juno Therapeutics, ... | FLATLEY JAY T | Director | Option Exercise | D | 23.29 | 12,000 | 279,480 | 0 | |
| Mar 07 2018 | JUNO | Juno Therapeutics, ... | FLATLEY JAY T | Director | Option Exercise | D | 24.07 | 18,000 | 433,260 | 0 | |
| Mar 07 2018 | JUNO | Juno Therapeutics, ... | FLATLEY JAY T | Director | Sell | U | 87.00 | 31,500 | 2,740,500 | 0 | 31.5 K to 0 (-100.00 %) |
| Mar 07 2018 | JUNO | Juno Therapeutics, ... | EVNIN ANTHONY B | Director | Option Exercise | D | 23.29 | 12,000 | 279,480 | 0 | |
| Mar 07 2018 | JUNO | Juno Therapeutics, ... | EVNIN ANTHONY B | Director | Option Exercise | D | 42.40 | 12,000 | 508,800 | 0 | |
| Mar 07 2018 | JUNO | Juno Therapeutics, ... | EVNIN ANTHONY B | Director | Option Exercise | D | 60.00 | 12,000 | 720,000 | 0 | |
| Mar 07 2018 | JUNO | Juno Therapeutics, ... | EVNIN ANTHONY B | Director | Gift | G | 0.00 | 34,842 | 0 | 0 | 34.8 K to 0 (-100.00 %) |
| Mar 07 2018 | JUNO | Juno Therapeutics, ... | EVNIN ANTHONY B | Director | Gift | G | 0.00 | 25,000 | 0 | 34,842 | 59.8 K to 34.8 K (-41.78 %) |
| Mar 07 2018 | JUNO | Juno Therapeutics, ... | Daniel Thomas O | Director | Option Exercise | D | 23.29 | 12,000 | 279,480 | 0 | |
| Mar 07 2018 | JUNO | Juno Therapeutics, ... | Cassidy Bernard J | General Counsel & S ... | Option Exercise | D | 20.76 | 113,636 | 2,359,083 | 0 | |
| Mar 07 2018 | JUNO | Juno Therapeutics, ... | Cassidy Bernard J | General Counsel & S ... | Option Exercise | D | 24.50 | 75,000 | 1,837,500 | 0 | |
| Mar 07 2018 | JUNO | Juno Therapeutics, ... | Cassidy Bernard J | General Counsel & S ... | Option Exercise | D | 48.06 | 50,500 | 2,427,030 | 0 | |
| Mar 07 2018 | JUNO | Juno Therapeutics, ... | Cassidy Bernard J | General Counsel & S ... | Option Exercise | D | 8.72 | 37,500 | 327,000 | 0 | |
| Mar 07 2018 | JUNO | Juno Therapeutics, ... | Cassidy Bernard J | General Counsel & S ... | Option Exercise | D | 6.36 | 125,000 | 795,000 | 0 | |
| Mar 07 2018 | JUNO | Juno Therapeutics, ... | Cassidy Bernard J | General Counsel & S ... | Sell | U | 87.00 | 26,869 | 2,337,603 | 0 | 26.9 K to 0 (-100.00 %) |
| Mar 07 2018 | JUNO | Juno Therapeutics, ... | Cassidy Bernard J | General Counsel & S ... | Sell | D | 0.00 | 35,893 | 0 | 0 | 35.9 K to 0 (-100.00 %) |
| Mar 07 2018 | JUNO | Juno Therapeutics, ... | Cassidy Bernard J | General Counsel & S ... | Sell | D | 0.00 | 25,639 | 0 | 35,893 | 61.5 K to 35.9 K (-41.67 %) |
| Mar 07 2018 | JUNO | Juno Therapeutics, ... | Cassidy Bernard J | General Counsel & S ... | Sell | D | 0.00 | 18,293 | 0 | 61,532 | 79.8 K to 61.5 K (-22.92 %) |
| Mar 07 2018 | JUNO | Juno Therapeutics, ... | Cassidy Bernard J | General Counsel & S ... | Sell | U | 87.00 | 5,558 | 483,546 | 79,825 | 85.4 K to 79.8 K (-6.51 %) |
| Mar 07 2018 | JUNO | Juno Therapeutics, ... | Bishop Hans Edgar | CEO & President | Option Exercise | D | 20.76 | 205,823 | 4,272,885 | 0 | |
| Mar 07 2018 | JUNO | Juno Therapeutics, ... | Bishop Hans Edgar | CEO & President | Option Exercise | D | 24.50 | 200,000 | 4,900,000 | 0 | |
| Mar 07 2018 | JUNO | Juno Therapeutics, ... | Bishop Hans Edgar | CEO & President | Option Exercise | D | 48.06 | 140,000 | 6,728,400 | 0 | |
| Mar 07 2018 | JUNO | Juno Therapeutics, ... | Bishop Hans Edgar | CEO & President | Option Exercise | D | 6.36 | 451,756 | 2,873,168 | 0 | |
| Mar 07 2018 | JUNO | Juno Therapeutics, ... | Bishop Hans Edgar | CEO & President | Sell | D | 0.00 | 35,893 | 0 | 0 | 35.9 K to 0 (-100.00 %) |
| Mar 07 2018 | JUNO | Juno Therapeutics, ... | Bishop Hans Edgar | CEO & President | Sell | D | 0.00 | 66,426 | 0 | 35,893 | 102.3 K to 35.9 K (-64.92 %) |
| Mar 07 2018 | JUNO | Juno Therapeutics, ... | Bishop Hans Edgar | CEO & President | Sell | D | 0.00 | 33,133 | 0 | 102,319 | 135.5 K to 102.3 K (-24.46 %) |
| Mar 07 2018 | JUNO | Juno Therapeutics, ... | Bishop Hans Edgar | CEO & President | Sell | D | 87.00 | 48,829 | 4,248,123 | 135,452 | 184.3 K to 135.5 K (-26.50 %) |
| Mar 07 2018 | JUNO | Juno Therapeutics, ... | Bishop Hans Edgar | CEO & President | Sell | U | 87.00 | 2,263,948 | 196,963,476 | 184,281 | 2.4 M to 184.3 K (-92.47 %) |
| Mar 07 2018 | JUNO | Juno Therapeutics, ... | Barron Hal | Director | Option Exercise | D | 23.29 | 12,000 | 279,480 | 0 | |
| Mar 07 2018 | JUNO | Juno Therapeutics, ... | Barron Hal | Director | Option Exercise | D | 42.40 | 12,000 | 508,800 | 0 | |
| Mar 07 2018 | JUNO | Juno Therapeutics, ... | Barron Hal | Director | Option Exercise | D | 60.00 | 12,000 | 720,000 | 0 | |
| Mar 07 2018 | JUNO | Juno Therapeutics, ... | Barron Hal | Director | Option Exercise | D | 6.36 | 75,000 | 477,000 | 0 | |
| Mar 07 2018 | JUNO | Juno Therapeutics, ... | Barron Hal | Director | Sell | D | 87.00 | 3,780 | 328,860 | 0 | 3.8 K to 0 (-100.00 %) |
| Mar 07 2018 | JUNO | Juno Therapeutics, ... | Barron Hal | Director | Sell | U | 87.00 | 100,000 | 8,700,000 | 3,780 | 103.8 K to 3.8 K (-96.36 %) |
| Mar 07 2018 | JUNO | Juno Therapeutics, ... | Azelby Robert | EVP & Chief Commerc ... | Option Exercise | D | 20.76 | 98,545 | 2,045,794 | 0 | |
| Mar 07 2018 | JUNO | Juno Therapeutics, ... | Azelby Robert | EVP & Chief Commerc ... | Option Exercise | D | 25.29 | 30,002 | 758,751 | 0 | |
| Mar 07 2018 | JUNO | Juno Therapeutics, ... | Azelby Robert | EVP & Chief Commerc ... | Option Exercise | D | 51.76 | 93,294 | 4,828,897 | 0 | |
| Mar 07 2018 | JUNO | Juno Therapeutics, ... | Azelby Robert | EVP & Chief Commerc ... | Sell | D | 0.00 | 35,893 | 0 | 0 | 35.9 K to 0 (-100.00 %) |
| Mar 07 2018 | JUNO | Juno Therapeutics, ... | Azelby Robert | EVP & Chief Commerc ... | Sell | D | 0.00 | 25,639 | 0 | 35,893 | 61.5 K to 35.9 K (-41.67 %) |
| Mar 07 2018 | JUNO | Juno Therapeutics, ... | Azelby Robert | EVP & Chief Commerc ... | Sell | D | 0.00 | 20,580 | 0 | 61,532 | 82.1 K to 61.5 K (-25.06 %) |
| Mar 07 2018 | JUNO | Juno Therapeutics, ... | Azelby Robert | EVP & Chief Commerc ... | Sell | D | 0.00 | 7,500 | 0 | 82,112 | 89.6 K to 82.1 K (-8.37 %) |
| Mar 07 2018 | JUNO | Juno Therapeutics, ... | AGARWAL SUNIL | President of R & D | Option Exercise | D | 24.01 | 313,797 | 7,534,266 | 0 | |
| Mar 07 2018 | JUNO | Juno Therapeutics, ... | AGARWAL SUNIL | President of R & D | Sell | D | 0.00 | 35,893 | 0 | 0 | 35.9 K to 0 (-100.00 %) |
| Mar 07 2018 | JUNO | Juno Therapeutics, ... | AGARWAL SUNIL | President of R & D | Sell | D | 0.00 | 29,135 | 0 | 35,893 | 65 K to 35.9 K (-44.80 %) |
| Mar 07 2018 | JUNO | Juno Therapeutics, ... | AGARWAL SUNIL | President of R & D | Sell | D | 0.00 | 84,549 | 0 | 65,028 | 149.6 K to 65 K (-56.53 %) |
| Mar 01 2018 | JUNO | Juno Therapeutics, ... | Harr Steve | CFO & Head, Corp. D ... | Grant | A | 0.00 | 11,544 | 0 | 639,517 | 628 K to 639.5 K (+1.84 %) |
| Feb 14 2018 | JUNO | Juno Therapeutics, ... | Azelby Robert | EVP & Chief Commerc ... | Sell | S | 85.55 | 4,157 | 355,631 | 89,614 | 93.8 K to 89.6 K (-4.43 %) |
| Feb 09 2018 | JUNO | Juno Therapeutics, ... | Harr Steve | CFO & Head, Corp. D ... | Gift | G | 0.00 | 162,790 | 0 | 627,973 | 790.8 K to 628 K (-20.59 %) |
| Feb 09 2018 | JUNO | Juno Therapeutics, ... | Harr Steve | CFO & Head, Corp. D ... | Payment of Exercise | F | 85.49 | 1,704 | 145,675 | 790,763 | 792.5 K to 790.8 K (-0.22 %) |
| Feb 09 2018 | JUNO | Juno Therapeutics, ... | Cassidy Bernard J | General Counsel & S ... | Gift | G | 0.00 | 26,634 | 0 | 85,262 | 111.9 K to 85.3 K (-23.80 %) |
| Feb 09 2018 | JUNO | Juno Therapeutics, ... | Cassidy Bernard J | General Counsel & S ... | Payment of Exercise | F | 85.49 | 1,528 | 130,629 | 111,896 | 113.4 K to 111.9 K (-1.35 %) |
| Feb 09 2018 | JUNO | Juno Therapeutics, ... | Bishop Hans Edgar | CEO & President | Gift | G | 0.00 | 116,280 | 0 | 2,448,229 | 2.6 M to 2.4 M (-4.53 %) |
| Feb 09 2018 | JUNO | Juno Therapeutics, ... | Bishop Hans Edgar | CEO & President | Payment of Exercise | F | 85.49 | 4,346 | 371,540 | 2,564,509 | 2.6 M to 2.6 M (-0.17 %) |
| Feb 09 2018 | JUNO | Juno Therapeutics, ... | Azelby Robert | EVP & Chief Commerc ... | Option Exercise | M | 20.76 | 2,663 | 55,284 | 98,545 | |
| Feb 09 2018 | JUNO | Juno Therapeutics, ... | Azelby Robert | EVP & Chief Commerc ... | Option Exercise | M | 25.29 | 834 | 21,092 | 30,002 | |
| Feb 09 2018 | JUNO | Juno Therapeutics, ... | Azelby Robert | EVP & Chief Commerc ... | Sell | S | 85.77 | 3,497 | 299,938 | 93,771 | 97.3 K to 93.8 K (-3.60 %) |
| Feb 09 2018 | JUNO | Juno Therapeutics, ... | Azelby Robert | EVP & Chief Commerc ... | Buy | M | 20.76 | 2,663 | 55,284 | 97,268 | 94.6 K to 97.3 K (+2.81 %) |
| Feb 09 2018 | JUNO | Juno Therapeutics, ... | Azelby Robert | EVP & Chief Commerc ... | Buy | M | 25.29 | 834 | 21,092 | 94,605 | 93.8 K to 94.6 K (+0.89 %) |
| Feb 09 2018 | JUNO | Juno Therapeutics, ... | Azelby Robert | EVP & Chief Commerc ... | Payment of Exercise | F | 85.49 | 2,700 | 230,823 | 93,771 | 96.5 K to 93.8 K (-2.80 %) |
| Feb 02 2018 | JUNO | Juno Therapeutics, ... | LEE ANN L. | EVP, Technical Oper ... | Grant | A | 0.00 | 40,788 | 0 | 110,792 | 70 K to 110.8 K (+58.27 %) |
| Feb 02 2018 | JUNO | Juno Therapeutics, ... | Harr Steve | CFO & Head, Corp. D ... | Grant | A | 0.00 | 29,135 | 0 | 792,467 | 763.3 K to 792.5 K (+3.82 %) |
| Feb 02 2018 | JUNO | Juno Therapeutics, ... | Cassidy Bernard J | General Counsel & S ... | Grant | A | 0.00 | 25,639 | 0 | 113,424 | 87.8 K to 113.4 K (+29.21 %) |
| Feb 02 2018 | JUNO | Juno Therapeutics, ... | Bishop Hans Edgar | CEO & President | Grant | A | 0.00 | 66,426 | 0 | 2,568,855 | 2.5 M to 2.6 M (+2.65 %) |
| Feb 02 2018 | JUNO | Juno Therapeutics, ... | Azelby Robert | EVP & Chief Commerc ... | Option Exercise | M | 51.76 | 4,167 | 215,684 | 93,294 | |
| Feb 02 2018 | JUNO | Juno Therapeutics, ... | Azelby Robert | EVP & Chief Commerc ... | Sell | S | 85.78 | 4,167 | 357,445 | 96,471 | 100.6 K to 96.5 K (-4.14 %) |
| Feb 02 2018 | JUNO | Juno Therapeutics, ... | Azelby Robert | EVP & Chief Commerc ... | Buy | M | 51.76 | 4,167 | 215,684 | 100,638 | 96.5 K to 100.6 K (+4.32 %) |
| Feb 02 2018 | JUNO | Juno Therapeutics, ... | Azelby Robert | EVP & Chief Commerc ... | Grant | A | 0.00 | 25,639 | 0 | 96,471 | 70.8 K to 96.5 K (+36.20 %) |
| Feb 02 2018 | JUNO | Juno Therapeutics, ... | AGARWAL SUNIL | President of R & D | Grant | A | 0.00 | 29,135 | 0 | 149,577 | 120.4 K to 149.6 K (+24.19 %) |
| Jan 30 2018 | JUNO | Juno Therapeutics, ... | FLATLEY JAY T | Director | Buy | P | 22.92 | 10,000 | 229,200 | 31,500 | 21.5 K to 31.5 K (+46.51 %) |
| Jan 24 2018 | JUNO | Juno Therapeutics, ... | Azelby Robert | EVP & Chief Commerc ... | Option Exercise | M | 51.76 | 102,539 | 5,307,419 | 97,461 | |
| Jan 24 2018 | JUNO | Juno Therapeutics, ... | Azelby Robert | EVP & Chief Commerc ... | Sell | S | 86.25 | 102,539 | 8,843,989 | 70,832 | 173.4 K to 70.8 K (-59.14 %) |
| Jan 24 2018 | JUNO | Juno Therapeutics, ... | Azelby Robert | EVP & Chief Commerc ... | Buy | M | 51.76 | 102,539 | 5,307,419 | 173,371 | 70.8 K to 173.4 K (+144.76 %) |
| Jan 19 2018 | JUNO | Juno Therapeutics, ... | Azelby Robert | EVP & Chief Commerc ... | Option Exercise | M | 20.76 | 26,633 | 552,901 | 101,208 | |
| Jan 19 2018 | JUNO | Juno Therapeutics, ... | Azelby Robert | EVP & Chief Commerc ... | Option Exercise | M | 25.29 | 2,498 | 63,174 | 30,836 | |
| Jan 19 2018 | JUNO | Juno Therapeutics, ... | Azelby Robert | EVP & Chief Commerc ... | Sell | S | 69.95 | 7,990 | 558,901 | 70,832 | 78.8 K to 70.8 K (-10.14 %) |
| Jan 19 2018 | JUNO | Juno Therapeutics, ... | Azelby Robert | EVP & Chief Commerc ... | Sell | S | 68.10 | 21,141 | 1,439,702 | 78,822 | 100 K to 78.8 K (-21.15 %) |
| Jan 19 2018 | JUNO | Juno Therapeutics, ... | Azelby Robert | EVP & Chief Commerc ... | Buy | M | 20.76 | 26,633 | 552,901 | 99,963 | 73.3 K to 100 K (+36.32 %) |
| Jan 19 2018 | JUNO | Juno Therapeutics, ... | Azelby Robert | EVP & Chief Commerc ... | Buy | M | 25.29 | 2,498 | 63,174 | 73,330 | 70.8 K to 73.3 K (+3.53 %) |
| Jan 19 2018 | JUNO | Juno Therapeutics, ... | Azelby Robert | EVP & Chief Commerc ... | Option Exercise | M | 20.76 | 26,633 | 552,901 | 101,208 | |
| Jan 19 2018 | JUNO | Juno Therapeutics, ... | Azelby Robert | EVP & Chief Commerc ... | Option Exercise | M | 25.29 | 2,498 | 63,174 | 30,836 | |
| Jan 19 2018 | JUNO | Juno Therapeutics, ... | Azelby Robert | EVP & Chief Commerc ... | Sell | S | 69.95 | 7,990 | 558,901 | 70,832 | 78.8 K to 70.8 K (-10.14 %) |
| Jan 19 2018 | JUNO | Juno Therapeutics, ... | Azelby Robert | EVP & Chief Commerc ... | Sell | S | 68.10 | 21,141 | 1,439,702 | 78,822 | 100 K to 78.8 K (-21.15 %) |
| Jan 19 2018 | JUNO | Juno Therapeutics, ... | Azelby Robert | EVP & Chief Commerc ... | Buy | M | 20.76 | 26,633 | 552,901 | 99,963 | 73.3 K to 100 K (+36.32 %) |
| Jan 19 2018 | JUNO | Juno Therapeutics, ... | Azelby Robert | EVP & Chief Commerc ... | Buy | M | 25.29 | 2,498 | 63,174 | 73,330 | 70.8 K to 73.3 K (+3.53 %) |
| Jan 18 2018 | JUNO | Juno Therapeutics, ... | Bishop Hans Edgar | CEO & President | Option Exercise | M | 6.36 | 245,750 | 1,562,970 | 451,756 | |
| Jan 18 2018 | JUNO | Juno Therapeutics, ... | Bishop Hans Edgar | CEO & President | Sell | S | 48.56 | 42,457 | 2,061,916 | 2,502,429 | 2.5 M to 2.5 M (-1.67 %) |
| Jan 18 2018 | JUNO | Juno Therapeutics, ... | Bishop Hans Edgar | CEO & President | Sell | S | 47.69 | 23,003 | 1,097,071 | 2,544,886 | 2.6 M to 2.5 M (-0.90 %) |
| Jan 18 2018 | JUNO | Juno Therapeutics, ... | Bishop Hans Edgar | CEO & President | Sell | S | 46.52 | 49,082 | 2,283,525 | 2,567,889 | 2.6 M to 2.6 M (-1.88 %) |
| Jan 18 2018 | JUNO | Juno Therapeutics, ... | Bishop Hans Edgar | CEO & President | Sell | S | 45.53 | 89,888 | 4,092,789 | 2,616,971 | 2.7 M to 2.6 M (-3.32 %) |
| Jan 18 2018 | JUNO | Juno Therapeutics, ... | Bishop Hans Edgar | CEO & President | Sell | S | 44.72 | 65,820 | 2,943,227 | 2,706,859 | 2.8 M to 2.7 M (-2.37 %) |
| Jan 18 2018 | JUNO | Juno Therapeutics, ... | Bishop Hans Edgar | CEO & President | Buy | M | 6.36 | 245,750 | 1,562,970 | 2,772,679 | 2.5 M to 2.8 M (+9.73 %) |
| Jan 09 2018 | JUNO | Juno Therapeutics, ... | PIEN HOWARD H | Director | Grant | A | 0.00 | 417 | 0 | 130,050 | 129.6 K to 130.1 K (+0.32 %) |
| Jan 09 2018 | JUNO | Juno Therapeutics, ... | PIEN HOWARD H | Director | Gift | G | 0.00 | 25,000 | 0 | 129,633 | 154.6 K to 129.6 K (-16.17 %) |
| Jan 09 2018 | JUNO | Juno Therapeutics, ... | NELSEN ROBERT | Director | Grant | A | 0.00 | 237 | 0 | 54,058 | 53.8 K to 54.1 K (+0.44 %) |
| Jan 09 2018 | JUNO | Juno Therapeutics, ... | Klausner Richard | Director | Sell | S | 49.37 | 918 | 45,321 | 728,775 | 729.7 K to 728.8 K (-0.13 %) |
| Jan 09 2018 | JUNO | Juno Therapeutics, ... | Klausner Richard | Director | Sell | S | 48.95 | 4,846 | 237,223 | 729,693 | 734.5 K to 729.7 K (-0.66 %) |
| Jan 09 2018 | JUNO | Juno Therapeutics, ... | Klausner Richard | Director | Sell | S | 47.80 | 5,011 | 239,538 | 734,539 | 739.6 K to 734.5 K (-0.68 %) |
| Jan 09 2018 | JUNO | Juno Therapeutics, ... | Klausner Richard | Director | Sell | S | 46.85 | 1,949 | 91,310 | 739,550 | 741.5 K to 739.6 K (-0.26 %) |
| Jan 09 2018 | JUNO | Juno Therapeutics, ... | Klausner Richard | Director | Grant | A | 0.00 | 248 | 0 | 741,499 | 741.3 K to 741.5 K (+0.03 %) |
| Jan 09 2018 | JUNO | Juno Therapeutics, ... | EVNIN ANTHONY B | Director | Grant | A | 0.00 | 150 | 0 | 59,842 | 59.7 K to 59.8 K (+0.25 %) |
| Jan 09 2018 | JUNO | Juno Therapeutics, ... | Barron Hal | Director | Grant | A | 0.00 | 336 | 0 | 103,780 | 103.4 K to 103.8 K (+0.32 %) |
| Dec 22 2017 | JUNO | Juno Therapeutics, ... | Harr Steve | CFO & Head, Corp. D ... | Option Exercise | M | 8.72 | 8,750 | 76,300 | 98,750 | |
| Dec 22 2017 | JUNO | Juno Therapeutics, ... | Harr Steve | CFO & Head, Corp. D ... | Sell | S | 45.18 | 500 | 22,591 | 763,332 | 763.8 K to 763.3 K (-0.07 %) |
| Dec 22 2017 | JUNO | Juno Therapeutics, ... | Harr Steve | CFO & Head, Corp. D ... | Sell | S | 44.74 | 8,250 | 369,083 | 763,832 | 772.1 K to 763.8 K (-1.07 %) |
| Dec 22 2017 | JUNO | Juno Therapeutics, ... | Harr Steve | CFO & Head, Corp. D ... | Buy | M | 8.72 | 8,750 | 76,300 | 772,082 | 763.3 K to 772.1 K (+1.15 %) |
| Dec 22 2017 | JUNO | Juno Therapeutics, ... | Klausner Richard | Director | Sell | S | 45.16 | 3,141 | 141,849 | 741,251 | 744.4 K to 741.3 K (-0.42 %) |
| Dec 22 2017 | JUNO | Juno Therapeutics, ... | Klausner Richard | Director | Sell | S | 44.72 | 32,859 | 1,469,507 | 744,392 | 777.3 K to 744.4 K (-4.23 %) |
| Dec 20 2017 | JUNO | Juno Therapeutics, ... | Azelby Robert | EVP & Chief Commerc ... | Sell | S | 44.96 | 1,816 | 81,647 | 70,832 | 72.6 K to 70.8 K (-2.50 %) |
| Nov 28 2017 | JUNO | Juno Therapeutics, ... | LEE ANN L. | EVP, Technical Oper ... | Option Exercise | A | 62.85 | 152,900 | 9,609,765 | 152,900 | |
| Nov 28 2017 | JUNO | Juno Therapeutics, ... | LEE ANN L. | EVP, Technical Oper ... | Grant | A | 0.00 | 35,000 | 0 | 70,004 | 35 K to 70 K (+99.99 %) |
| Nov 28 2017 | JUNO | Juno Therapeutics, ... | LEE ANN L. | EVP, Technical Oper ... | Grant | A | 0.00 | 35,004 | 0 | 35,004 | 0 to 35 K |
| Nov 09 2017 | JUNO | Juno Therapeutics, ... | Azelby Robert | EVP & Chief Commerc ... | Payment of Exercise | F | 55.98 | 684 | 38,290 | 72,648 | 73.3 K to 72.6 K (-0.93 %) |
| Nov 03 2017 | JUNO | Juno Therapeutics, ... | Azelby Robert | EVP & Chief Commerc ... | Option Exercise | M | 25.29 | 6,666 | 168,583 | 33,334 | |
| Nov 03 2017 | JUNO | Juno Therapeutics, ... | Azelby Robert | EVP & Chief Commerc ... | Sell | S | 54.95 | 6,666 | 366,297 | 73,332 | 80 K to 73.3 K (-8.33 %) |